Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.
Part of paid clinical trials in Sacramento, California.
- Sponsor
- Integrative Skin Science and Research
- Study ID
- NCT07560618
- Phase
- PHASE4
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Roflumilast Cream 0.15% — DRUGtopically applied to the affected areas once daily
Study Details
This study is being done to obtain descriptive classifications of pruritus using a patient directed survey system and assess change in pruritus over time in patients with Atopic Dermatitis over 4 weeks with use of topical Roflumilast cream 0.15% QD.
Key Dates
- Start date
- Apr 30, 2026
- Status verified
- Apr 2026
- Primary completion
- Aug 31, 2027
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Roflumilast Group
Primary Outcome Measure
Number of descriptors (besides itch) used to describe skin sensations associated with AD [ Time Frame: From enrollment to end of treatment at 4 weeks. ]
Central Contacts
- Nasima Afzal Chief Operating Officer916-775-5080
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Integrative Skin Science and Research | Sacramento | California | 95815 | Raja Sivamani, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Sacramento, CA
By condition
By specialty
By research site
Related Studies
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisPHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama
- Molecular Signatures of Cutaneous Dupilumab ResponsePHASE4 · Recruiting · University of California, San Francisco · San Francisco, California
- Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECTRecruiting · University of California, San Diego · La Jolla, California
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisPHASE2 · Recruiting · Pfizer · Birmingham, Alabama